{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:07:45Z","timestamp":1794276465804,"version":"4.9.0"},"reference-count":51,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"unspecified","delay-in-days":68,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["egastro"],"accepted":{"date-parts":[[2025,5,19]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>The new European clinical practice guidelines from three scientific societies (European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity) on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) provide detailed recommendations on diagnosis, risk stratification, monitoring strategies, treatment and prevention. Lifestyle interventions (eg, weight reduction, Mediterranean diet, exercise, alcohol abstinence) and the treatment of cardiometabolic risk factors continue to be the mainstay of treatment and prevention of the disease. Incretin mimetics that are approved to treat obesity and\/or type 2 diabetes such as semaglutide and tirzepatide have benefits for ameliorating metabolic dysfunction-associated steatohepatitis (MASH). Novel developments include adapted strategies for screening (case finding) using non-invasive tests (NITs) with a focus on detecting fibrosis or cirrhosis, risk-adjusted monitoring of MASLD by NITs as well as the recommendation to use, if locally approved, the thyroid hormone receptor \u03b2-agonist resmetirom in patients with non-cirrhotic MASH fibrosis (\u2265F2 stage).<\/jats:p>","DOI":"10.1136\/egastro-2025-100196","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T15:50:29Z","timestamp":1749397829000},"page":"e100196","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Key takeaways from the updated multidisciplinary European MASLD guidelines"],"prefix":"10.1136","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8755-7703","authenticated-orcid":false,"given":"Paul","family":"Horn","sequence":"first","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum and Campus Charit\u00e9 Mitte, Berlin, Germany"},{"name":"Berlin Institute of Health at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charit\u00e9 Digital Clinician Scientist Program, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum and Campus Charit\u00e9 Mitte, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"key":"2025081719110323000_3.2.e100196.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"2025081719110323000_3.2.e100196.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"2025081719110323000_3.2.e100196.3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"key":"2025081719110323000_3.2.e100196.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.012"},{"key":"2025081719110323000_3.2.e100196.5","doi-asserted-by":"crossref","first-page":"155642","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"key":"2025081719110323000_3.2.e100196.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26761"},{"key":"2025081719110323000_3.2.e100196.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049767","article-title":"Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis","volume":"12","author":"Jarvis","year":"2022","journal-title":"BMJ Open"},{"key":"2025081719110323000_3.2.e100196.8","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00443-0"},{"key":"2025081719110323000_3.2.e100196.9","doi-asserted-by":"crossref","first-page":"101127","DOI":"10.1016\/j.jhepr.2024.101127","article-title":"Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score","volume":"6","author":"Sripongpun","year":"2024","journal-title":"JHEP Rep"},{"key":"2025081719110323000_3.2.e100196.10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/hepr.14133","article-title":"Distinct characteristics of MetALD (metabolic dysfunction-associated steatotic liver disease with greater alcohol consumption) in the general population","volume":"55","author":"Yoon","year":"2025","journal-title":"Hepatol Res"},{"key":"2025081719110323000_3.2.e100196.11","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/liv.15939","article-title":"Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence","volume":"44","author":"Ciardullo","year":"2024","journal-title":"Liver Int"},{"key":"2025081719110323000_3.2.e100196.12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/HEP.0000000000000925","article-title":"MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up","volume":"81","author":"Kwak","year":"2025","journal-title":"Hepatology"},{"key":"2025081719110323000_3.2.e100196.13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jhep.2024.05.042","article-title":"Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort","volume":"81","author":"Oh","year":"2024","journal-title":"J Hepatol"},{"key":"2025081719110323000_3.2.e100196.14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(24)00427-8","article-title":"Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD","volume":"10","author":"Krag","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081719110323000_3.2.e100196.15","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2024.01.006","article-title":"Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis","volume":"22","author":"Nasr","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025081719110323000_3.2.e100196.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"2025081719110323000_3.2.e100196.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.031"},{"key":"2025081719110323000_3.2.e100196.18","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00141-3"},{"key":"2025081719110323000_3.2.e100196.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028"},{"key":"2025081719110323000_3.2.e100196.20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322572"},{"key":"2025081719110323000_3.2.e100196.21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323082"},{"key":"2025081719110323000_3.2.e100196.22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025081719110323000_3.2.e100196.23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324191"},{"key":"2025081719110323000_3.2.e100196.24","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyab174"},{"key":"2025081719110323000_3.2.e100196.25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.gastro.2018.03.038","article-title":"Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease","volume":"155","author":"Ma","year":"2018","journal-title":"Gastroenterology"},{"key":"2025081719110323000_3.2.e100196.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01701-3"},{"key":"2025081719110323000_3.2.e100196.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263931","article-title":"Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"17","author":"Fern\u00e1ndez","year":"2022","journal-title":"PLoS One"},{"key":"2025081719110323000_3.2.e100196.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154455"},{"key":"2025081719110323000_3.2.e100196.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2022.06.037"},{"key":"2025081719110323000_3.2.e100196.30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"2025081719110323000_3.2.e100196.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.08.011"},{"key":"2025081719110323000_3.2.e100196.32","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.jhepr.2021.100253","article-title":"Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD","volume":"3","author":"Oh","year":"2021","journal-title":"JHEP Rep"},{"key":"2025081719110323000_3.2.e100196.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"2025081719110323000_3.2.e100196.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"2025081719110323000_3.2.e100196.35","doi-asserted-by":"crossref","unstructured":"Sanyal AJ , Newsome PN , Kliers I , et al . Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med 2025. doi:10.1056\/NEJMoa2413258. Online ahead of print.","DOI":"10.1056\/NEJMoa2413258"},{"key":"2025081719110323000_3.2.e100196.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"2025081719110323000_3.2.e100196.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"2025081719110323000_3.2.e100196.38","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165"},{"key":"2025081719110323000_3.2.e100196.39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.15331","article-title":"Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"50","author":"Vilar-Gomez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025081719110323000_3.2.e100196.40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cgh.2020.04.083","article-title":"Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis","volume":"19","author":"Vilar-Gomez","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025081719110323000_3.2.e100196.41","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.053"},{"key":"2025081719110323000_3.2.e100196.42","doi-asserted-by":"crossref","first-page":"104392","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"key":"2025081719110323000_3.2.e100196.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"2025081719110323000_3.2.e100196.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00634-7"},{"key":"2025081719110323000_3.2.e100196.45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19569"},{"key":"2025081719110323000_3.2.e100196.46","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24418"},{"key":"2025081719110323000_3.2.e100196.47","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatology"},{"key":"2025081719110323000_3.2.e100196.48","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.clnu.2023.03.021","article-title":"Practical guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN\/UEG guideline","volume":"42","author":"Bischoff","year":"2023","journal-title":"Clin Nutr"},{"key":"2025081719110323000_3.2.e100196.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.022"},{"key":"2025081719110323000_3.2.e100196.50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cgh.2012.09.025","article-title":"Association between anthropometric parameters and measurements of liver stiffness by transient elastography","volume":"11","author":"Wong","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025081719110323000_3.2.e100196.51","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000994"}],"container-title":["eGastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/egastro-2025-100196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T02:15:06Z","timestamp":1755483306000},"score":1,"resource":{"primary":{"URL":"http:\/\/egastroenterology.bmj.com\/lookup\/doi\/10.1136\/egastro-2025-100196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,8]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/egastro-2025-100196"],"URL":"https:\/\/doi.org\/10.1136\/egastro-2025-100196","relation":{},"ISSN":["2766-0125","2976-7296"],"issn-type":[{"value":"2766-0125","type":"print"},{"value":"2976-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}